Browsing by Author "Atmaca, Mukadder"

Now showing 1 - 2 of 2

Importance of Curcumin Effect and Asprosin Level on Glucose Metabolism in Diabetic Rats
(2023) Gökdemir, Mehmet Tahir; Taşdemir, Ezel; Yokus, Beran; Atmaca, Mukadder; Gokdemir, Gul Sahika
Asprosin is a new hormone secreted mainly from white adipose tissue. It may be associated with the pathogenesis of obesity, diabetes and some metabolic diseases. The changes in plasma asprosin levels of experimental diabetic rats and the relation of these changes with liver glucose metabolism and some diabetes parameters were investigated, and the effects of metformin, gliclazide or curcumin treatment on plasma asprosin levels were tried. The study was designed as an animal model in diabetic rats The albino rats were divided into five groups. To induce diabetes, a single dose of STZ was injected intraperitoneally. Diabetics rats were treated intragastrically with metformin (D+Metformin group), gliclazide (D+Giliclazide group) or 20 curcumin (D+Curcumin group) for eight weeks. Fasting blood glucose, insulin levels and other parameters were measured. Plasma asporsin levels of untreated diabetic rats increased significantly (P<.001). Although the plasma asprosin levels of diabetic rats treated with the rugs were significantly lower (P<.001). Fasting blood glucose levels of diabetic rats treated with the drugs were found to be remarkably lower than the diabetic control values (P<.001, respectively). There was no significant difference in the insulin levels and HOMA- IR between these three groups. Curcumin treatment provides significant improvements in plasma asprosin level and diabetes parameters. The increase in plasma asprosin level in diabetic rats may be one of the main reasons that facilitate the development of the disease or is responsible for its pathogenesis. Our findings support the idea that curcumin may be an important treatment option for diabetes.
The Effect of Gliclazide Use on BDNF and NGF Levels in Rats with Diabetes Mellitus
(2023) Gokdemir, Gul Sahika; Atmaca, Mukadder
Objective: In this study, the effects of gliclazides, a second generation sulfonylurea group, on BDNF and NGF plasma levels, which are considered neurodegeneration biomarkers, will be examined. When designing our study, we assumed that gliazides might have positive neu- ronal effects. Thus, the possible positive effects of gliclazide will be emphasized in our study. Methods: In the experiment, 21 adult male Wistar-Albino rats were used. Serum BDNF and NGF levels were determined by analyzing with enzyme-linked immunosorbent assay kit in accordance with the recommendations. Results: BDNF levels were significantly lower in gliclazide-treated diabetic rats and non- medicated diabetic rats compared to the healthy control group (p=0.017, p<0.001, re- spectively). Although the BDNF level of rats with diabetes given gliclazide was increased compared to rats with and without diabetes, this difference was not significant (p=0.107). Similarly, NGF levels were significantly lower in rats given gliclazide (p=0.009) and diabetic rats not given gliclazide (p=0.001) compared to the healthy control group. When the dia- betic groups were compared among themselves, although the NGF level was increased in the gliclazide group, this difference was not statistically significant (p=0.638). The differences between the groups were significant in cyclic AMP regulatory element binding (p<0.001), c-FOS (p<0.001), amyloid precursor protein (p<0.001), B-SECRETASE1 (p=0.004), and dou- blecortin (p<0.001) levels. Conclusion: As a result, serum BDNF and NGF levels were significantly higher in non-dia- betic healthy control group rats than in diabetic rats. While low serum levels of BDNF and NGF neurotrophins, which increase in neurodegeneration, were observed in diabetic rats, this level was observed to be higher in diabetic rats given gliclazide.